Growth Modulation of Freshly Isolated Non-Hodgkin's B-Lymphoma Cells Induced by Various Cytokines and All-Trans-Retinoic-Acid

References

• Tweeddale M. E., Nadir B. L., Robinson J., Zalcberg J., Lockwood G., Minden M., Messner H. A. The presence of clonogenic cells in high-grade malignant lymphoma: a prognostic factor. Blood 1987; 69: 1307–1314
   PubMed Web of Science ®Google Scholar
• Ford R. J., Kouttab N. M., Shasrabuddhe C. G., Davis F. M., Mehta S. R. Growth-factor mediated proliferation in B cell Non-Hodgkin's lymphomas. Blood 1985; 65: 1335–1341
   PubMed Web of Science ®Google Scholar
• Ford R. J., Goodacre A., Ramirez I., Mehta S. R., Cabanillas F. Establishment and characterization of human B-cell lymphoma lines using B-cell growth factor. Blood 1990; 75: 1311–1318
   PubMed Web of Science ®Google Scholar
• Taylor C. W., Grogan T. M., Salmon S. E. Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms. Blood. 1990; 75: 1114–1118
   PubMed Web of Science ®Google Scholar
• Yee C., Biondi A., Wang S. H., Iscove N. N., De Sousa J., Aarden L. A., Wong G. G., Clark S. C., Minden M. D. A possible autocrine role for interleukin-6 in two lymphoma cell lines. Blood 1989; 74: 798–804
   PubMed Web of Science ®Google Scholar
• Tweeddale M. E., Jamal N., Nguyen A., Wang X. H., Minden M. D., Messner H. A. Production of growth factors by malignant lymphoma cell lines. Blood. 1989; 74: 572–578
   PubMed Web of Science ®Google Scholar
• De France T., Fluckiger A. C., Rossi J. F., Magaud J. P., Sotto J. J., Banchereau J. Antiproliferative effects of interleukin-4 on freshly isolated non-Hodgkin's malignant B lymphoma cells. Blood 1992; 79: 990–996
   PubMed Web of Science ®Google Scholar
• Clayberger C., Luna-Fineman S., Lee J. E., Pillai A., Campbell M., Levy R., Krensky A. M. Interleukin 3 is a growth factor for human follicular B cell lymphoma. J. Exp. Med., 175: 371–376
   PubMed Web of Science ®Google Scholar
• Parkinson D. R., Sznol M., Cheson B. D. Biologic therapies for low-grade lymphomas. Semin. Oncol. 1993; 20: 111–117
   PubMed Web of Science ®Google Scholar
• Smalley R. V., Andersen J. W., Hawkins M. J., Bhide V., O'Connell M. J., Oken M. M., Borden E. C. Interferon alpha combined with cytotoxic therapy for patients with Non-Hodgkin's lymphoma. N. Engl. J. Med. 1992; 329: 1336–1341
   Web of Science ®Google Scholar
• Solal-Celigny P., Lepage E., Brousse N., Reyes F., Haioun C., Leporrier M., Peuchmaur M., Bosly A., Parlier Y., Brice P., Coiffier B., Gisselbrecht C. Recombinant interferon alpha-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N. Engl. J. Med. 1993; 329: 1608–1614
   PubMed Web of Science ®Google Scholar
• Jacob M. C., Piccinni M. P., Bonnefoix T., Sotto M. F., Couderc P., Bensa J. C., Sotto J. J. T lymphocytes from invaded lymph nodes patients with B-cell-derived Non-Hodgkin's Lymphoma: reactivity toward the malignant clone. Blood 1990; 75: 1154–1162
   PubMed Web of Science ®Google Scholar
• Masood R., Shang Y., Bond M. W., Scadden D. T., Moudgil T., Law R. E., Kaplan M. H., Jung B., Espina M., Lunardi-Iskandar Y., Levine A. M., Gill P. S. Interleukin-10 is an autocrine growth factor for acquired immunodeficiency syndrome-related B-cell lymphoma. Blood 1995; 85: 3423–3430
   PubMed Web of Science ®Google Scholar
• Santavenere E., Dipietro R., Centurione M. A., Trubiani O., Zamai L., Rana L. IL1 alpha antiproliferative and differentiative effects on Daudi lymphoma cells: multiparametric analysis. Cell Biol. Int. 1994; 18: 777–782
   PubMed Web of Science ®Google Scholar
• Lahm H., Fischer J. R., Reichert Y., Hederer R., Falk W., Debatin K. M., Krammer P. H. Autocrine growth factors secreted by the malignant human B-cell-line BJAB are distinct from other known cytokines. Eur. Cytokine Net. 1990; 1: 41–46
   PubMedGoogle Scholar
• Gibbons D. L., Rowe M., Cope A. P., Feldmann M., Brennan F. M. Lymphotoxin acts as an autocrine growth factor for Epstein-Barr virus-transformed B cells and differentiated Burkitt lymphoma cell lines. Eur. J. Immunol. 1994; 24: 1879–1885
   PubMed Web of Science ®Google Scholar
• Johnson P WM., Watt S. M., Betts D. R., Davies D., Jordan S., Norton A. J., Lister T. A. Isolated follicular lymphoma cells are resistant to apoptosis and can be grown in vitro in the CD40/stromal cell system. Blood 1993; 82: 1848–1857
   PubMed Web of Science ®Google Scholar
• Chen L., Mory Y., Zilberstein A., Revel M. Growth inhibition of human breast carcinoma and leukemia/lymphoma cell lines by recombinant interferon-β2. Proc. Natl. Acad. Sci. 1988; 85: 8037–8041
   PubMed Web of Science ®Google Scholar
• Bock G. H., Long C. A., Riley L. M., White J. D., Kurman C. C., Fleisher T. A., Tsokos M., Brown M., Serboused D., Schwietermann W. D., Nelson D. L. Characterization of a new IL6-dependent human B-lymphoma cell line in long-term culture. Cytokine 1993; 5: 480–489
   PubMed Web of Science ®Google Scholar
• Hall W., Hall E. Guidebook to cytokines and their receptors. Oxford University Press, Sambrook and Tooze 1994
   Google Scholar
• Stahl N., Farruggella J., Boulton T. G., Zhong Z., Darnell J. E., Yancopoulos G. D. Choice of STATS and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science 1995; 267: 1349–1353
   PubMed Web of Science ®Google Scholar
• Reittie J. E., Hoffbrand A. V. Interleukin-4 inhibits proliferation and spontaneous cytokine release by chronic lymphocytic leukemia cells. Leuk. Res. 1994; 18: 55–60
   PubMed Web of Science ®Google Scholar
• Ostlund L., Biberfeld P., Robert K. H., Christensson B., Einhorm S. Induction of proliferation and blast transformation by interferon in human malignant and non-malignant lymph node B cells. Blood. 1989; 73: 2171–2181
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C., Maraninchi D., Pico J. L., Milpied N., Coiffier B., Divine M., Tiberghien P., Bosly A., Tilly, Boulat H. O., Brandely M. Interleukin-2 treatment in lymphoma: a phase II multicenter study. Blood 1994; 83: 2081–2085
   PubMed Web of Science ®Google Scholar
• Weber J. S., Yand J. C., Topalian S. L., Schwartzentruber D. J., White D. E., Rosenberg S. A. The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with Non-Hodgkin's lymphoma. J. Clin. Oncol 1992; 10: 33–40
   PubMed Web of Science ®Google Scholar
• Margolin K. A., Aronson F. R., Sznol M., Atkins M. B., Ciobanu M., Fisher R. I., Weiss G. R., Doroshow J. H., Bar M. H., Hawkins M. J., Mier J. W., Paietta E., Gaynor E. P., Boldy D. H. Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and Non-Hodgkin's lymphoma. J. Immunother. 1991; 10: 214–222
   PubMed Web of Science ®Google Scholar
• Bernstein Z. P., Vaickus L., Friedman N., Goldrosen M. H., Watanabe H., Rahman R., Arbuck S. G., Sweenez J., Vesper D., Henderson E. D., Zeffren J., Dennin R. A., Levitt D., Foon K. A. Interleukin-2 lymphokine activated killer cells in Hodgkin's disease and non-Hodgkin's lymphoma. J. Immunother. 1991; 10: 141–146
   PubMed Web of Science ®Google Scholar
• Sznol M., Parkinson D. R. Interleukin-2 in therapy of hematologic malignancies. Blood 1994; 83: 2020–2022
   PubMed Web of Science ®Google Scholar
• Grignani F., Fagioli M., Alcalay M., Longo L., Pandolfi P. P., Donti E., Biondi A., Coco F. L., Grignani F., Pelkci P. G. Acute promyelocytic leukemia: from genetics to treatment. Blood 1994; 83: 10–25
   PubMed Web of Science ®Google Scholar
• Packer L. Retinoids. Part. B—Cell differentiation and clinical applications. Methods Enzymol. 1990; 190.
   PubMed Web of Science ®Google Scholar
• Turley J. M., Funakoshi S., Ruscetti F. W., Kasper L., Murphy W. J., Longo D. L., Brichenallroberts M. C. Growth inhibition and apoptosis of RL human B lymphoma cells by vitamine E succinate and retinoic acid: role for transforming growth factor beta. Cell Growth and Differentiation 1995; 6: 655–663
   PubMedGoogle Scholar
• Ogata A., Nishimoto N., Shima Y., Yoshizaki K., Kishimoto T. Inhibitory effect of all-trans retinoic acid on the growth of freshly isolated myeloma cells via interference with interleukin-6 signal transduction. Blood 1994; 84: 3040–3046
   PubMed Web of Science ®Google Scholar
• Shi I., Bonnefoix T., Heuzé-Levacon F., Jacob M. C., Leroux D. L., Gressin R., Sotto M. F., Chaffanjon P., Bensa J. C., Sotto J. J. Autotumor reactive T-cell clones among tumor-infiltrating T lymphocytes in B-cell Non-Hodgkin's lymphomas. Br. J. Hematol. 1995; 90: 837–843
   PubMed Web of Science ®Google Scholar